Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma/COPD-model rats

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 80, Issue 1, 2012, Pages 54-60

  Onoue, Satomi ^a   Sato, Hideyuki ^a   Ogawa, Kumiko ^a   Kojo, Yoshiki ^a   Aoki, Yosuke ^a   Kawabata, Yohei ^a,b   Wada, Koichi ^b   Mizumoto, Takahiro ^c,d   Yamada, Shizuo ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^c ILS Inc   (Japan)

^d American Peptide Company   (United States)

Author keywords

Cyclosporine A; Dissolution; Dry powder inhaler; Dry emulsion; Inflammation

Indexed keywords

ANTIGEN; CYCLOSPORIN A; EMULSIFYING AGENT; ERYTHRITOL; GLYCEROL OLEATE; LACTOSE; POVIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG FORMULATION; DRUG POTENCY; DRUG SOLUBILITY; DRY POWDER; EMULSION; LASER DIFFRACTION; MALE; NONHUMAN; PHYSICOCHEMICAL MODEL; RAT; SPRAY DRYING;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTHMA; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; DRUG CARRIERS; EMULSIFYING AGENTS; EMULSIONS; GLYCERIDES; LACTOSE; MALE; PARTICLE SIZE; POVIDONE; POWDERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 83955161684     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2011.10.003     Document Type: Article

References (23)

1. E. Calderon, R.F. Lockey, S.C. Bukantz, R.G. Coffey, and D.K. Ledford Is there a role for cyclosporine in asthma? J. Allergy Clin. Immunol. 89 1992 629 636
2. P.R. Beauchesne, N.S. Chung, and K.M. Wasan Cyclosporine A: a review of current oral and intravenous delivery systems Drug Dev. Ind. Pharm. 33 2007 211 220 (Pubitemid 46656047)
3. A.G. Alexander, N.C. Barnes, and A.B. Kay Trial of cyclosporin in corticosteroid-dependent chronic severe asthma Lancet 339 1992 324 328
4. J.F. Tjia, I.R. Webber, and D.J. Back Cyclosporin metabolism by the gastrointestinal mucosa Brit. J. Clin. Pharmacol. 31 1991 344 346
5. S. Rohatagi, F. Calic, N. Harding, M.L. Ozoux, J.P. Bouriot, S. Kirkesseli, L. DeLeij, and B.K. Jensen Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after single and repeated administration in healthy male and female subjects and asthmatic patients J. Clin. Pharmacol. 40 2000 1211 1226
6. B.A. Klyashchitsky, and A.J. Owen Nebulizer-compatible liquid formulations for aerosol pulmonary delivery of hydrophobic drugs: glucocorticoids and cyclosporine J. Drug Target 7 1999 79 99 (Pubitemid 29516012)
7. S. Onoue, H. Sato, Y. Kawabata, T. Mizumoto, N. Hashimoto, and S. Yamada In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy J. Control Release 138 2009 16 23
8. T. Vasconcelos, B. Sarmento, and P. Costa Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs Drug Discov. Today 12 2007 1068 1075 (Pubitemid 350186132)
9. J. Hatanaka, Y. Kimura, Z. Lai-Fu, S. Onoue, and S. Yamada Physicochemical and pharmacokinetic characterization of water-soluble Coenzyme Q(10) formulations Int. J. Pharm. 363 2008 112 117
10. S. Misaka, H. Sato, Y. Yamauchi, S. Onoue, and S. Yamada Novel dry powder formulation of ovalbumin for development of COPD-like animal model: Physicochemical characterization and biomarker profiling in rats Eur. J. Pharm. Sci. 37 2009 469 476
11. L. Wang, Y. Zhang, and X. Tang Characterization of a new inhalable thymopentin formulation Int. J. Pharm. 375 2009 1 7
12. V. Bertacche, E. Pini, R. Stradi, and F. Stratta Quantitative determination of amorphous cyclosporine in crystalline cyclosporine samples by Fourier transform infrared spectroscopy J. Pharm. Sci. 95 2006 159 166
13. S. Onoue, H. Sato, K. Ogawa, Y. Kawabata, T. Mizumoto, K. Yuminoki, N. Hashimoto, and S. Yamada Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach Int J Pharm 399 2010 94 101
14. G. Dollo, P. Le Corre, A. Guerin, F. Chevanne, J.L. Burgot, and R. Leverge Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs Eur. J. Pharm. Sci. 19 2003 273 280 (Pubitemid 36918420)
15. H.K. Chan Inhalation drug delivery devices and emerging technologies Expert Opin. Ther. Patents 13 2003 1333 1343
16. H. Larhrib, G.P. Martin, C. Marriott, and D. Prime The influence of carrier and drug morphology on drug delivery from dry powder formulations Int. J. Pharm. 257 2003 283 296 (Pubitemid 36507054)
17. E.G. Tzortzaki, M. Tsoumakidou, D. Makris, and N.M. Siafakas Laboratory markers for COPD in "susceptible" smokers Clin. Chim. Acta 364 2006 124 138 (Pubitemid 43120633)
18. R.A. Mathers, G.O. Evans, J. Bleby, and T. Tornow Total and differential leucocyte counts in rat and mouse bronchoalveolar lavage fluids using the Sysmex XT-2000iV Comp. Clin. Pathol. 16 2007 29 39 (Pubitemid 46140346)
19. P.J. Barnes Mediators of chronic obstructive pulmonary disease Pharmacol. Rev. 56 2004 515 548 (Pubitemid 39658462)
20. A. Szczeklik, E. Nizankowska, R. Dworski, B. Domagala, and G. Pinis Cyclosporin for steroid-dependent asthma Allergy 46 1991 312 315
21. S. Onoue, N. Hashimoto, and S. Yamada Dry powder inhalation systems for pulmonary delivery of therapeutic peptides and proteins Expert Opin. Ther. Patents 18 2008 429 442 (Pubitemid 351618752)
22. M. Bohdanecka, O. Schuck, M. Chadimova, J. Sedivy, A. Glagolicova, J. Skibova, J. Kunes, Z. Dobesova, M. Stuchlik, J. Vesela, and L. Kazdova The effect of omega-3 fatty acids and vitamin E on the nephrotoxicity of cyclosporin A in hereditary hypertriglyceridemic rats Physiol. Res. 48 1999 437 443 (Pubitemid 30019552)
23. R.J. Keenan, A. Zeevi, A.T. Iacono, K.J. Spichty, J.Z. Cai, S.A. Yousem, N.P. Ohori, I.L. Paradis, A. Kawai, and B.P. Griffith Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection: correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics Surgery 118 1995 385 391